68 results
8-K
EX-99.1
RNAZ
TransCode Therapeutics Inc
22 Jan 24
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
4:45pm
to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds from … pursuant to the offering, the satisfaction of customary closing conditions related to the offering, completion of the offering and various other factors
424B4
RNAZ
TransCode Therapeutics Inc
19 Jan 24
Prospectus supplement with pricing info
9:57pm
purchase warrants in this offering is expected to be made on or about January 22, 2024, subject to satisfaction of certain customary closing conditions … as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval from
8-K
EX-10.1
l39ha2
4 Dec 23
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
5:07pm
8-K
EX-4.1
s14aobc
4 Dec 23
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
5:07pm
8-K
EX-99.1
zn93xcn dlshy3vy7im
4 Dec 23
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
5:07pm
424B5
b8hyjza
1 Dec 23
Prospectus supplement for primary offering
5:23pm
424B5
uj988k5r
26 Oct 23
Prospectus supplement for primary offering
4:29pm
8-K
EX-99.1
lnjkw03x 0ow5da260
28 Sep 23
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
4:07pm